Association of early tumor shrinkage with survival in patients with HER2-positive advanced gastric cancer treated with trastuzumab deruxtecan.

被引：0
|
作者：
Fukuda, Koshiro
Ooki, Akira
Osumi, Hiroki
Fukuoka, Shota
Yoshino, Koichiro
Tamba, Mikako
Udagawa, Shohei
Shimozaki, Keitaro
Ogura, Mariko
Wakatsuki, Takeru
Chin, Keisho
Fujishiro, Mitsuhiro
Shinozaki, Eiji
Yamaguchi, Kensei
机构：
[1] Canc Inst Hosp Japanese Fdn Canc Res, Dept Gastroenterol Chemotherapy, Tokyo, Japan
[2] Canc Inst Hosp Japanese Fdn Canc Res, Dept Gastroenterol Chemotherapy, Koto, Japan
[3] Univ Tokyo, Dept Gastroenterol, Tokyo, Japan
[4] Japanese Fdn Canc Res, Canc Inst Hosp, Tokyo, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2025年 / 43卷 / 4_SUPPL期
关键词：
D O I：
10.1200/JCO.2025.43.4_suppl.360
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：360 / 360
页数：1
相关论文
共 50 条
  • [1] Trastuzumab deruxtecan in previously treated advanced HER2-positive gastric cancer
    Pamuk, Aylin
    Kuetting, Fabian
    Alakus, Hakan
    Bruns, Christiane
    ONKOLOGE, 2021, 27 (01): : 74 - 76
  • [2] Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer
    Shitara, Kohei
    Bang, Yung-Jue
    Iwasa, Satoru
    Sugimoto, Naotoshi
    Ryu, Min-Hee
    Sakai, Daisuke
    Chung, Hyun-Cheol
    Kawakami, Hisato
    Yabusaki, Hiroshi
    Lee, Jeeyun
    Saito, Kaku
    Kawaguchi, Yoshinori
    Kamio, Takahiro
    Kojima, Akihito
    Sugihara, Masahiro
    Yamaguchi, Kensei
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (25): : 2419 - 2430
  • [3] Trastuzumab deruxtecan for the treatment of patients with HER2-positive gastric cancer
    Kotani, Daisuke
    Shitara, Kohei
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2021, 13
  • [4] Trastuzumab deruxtecan for the treatment of HER2-positive gastric cancer
    Mishima, Saori
    Shitara, Kohei
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2021, 21 (07) : 825 - 830
  • [5] Trastuzumab deruxtecan for the treatment of HER2-positive advanced gastric cancer: a clinical perspective
    Masahiko Aoki
    Satoru Iwasa
    Narikazu Boku
    Gastric Cancer, 2021, 24 : 567 - 576
  • [6] Trastuzumab deruxtecan for the treatment of HER2-positive advanced gastric cancer: a clinical perspective
    Aoki, Masahiko
    Iwasa, Satoru
    Boku, Narikazu
    GASTRIC CANCER, 2021, 24 (03) : 567 - 576
  • [7] Trastuzumab Deruxtecan beim vortherapierten fortgeschrittenen HER2-positiven MagenkarzinomTrastuzumab deruxtecan in previously treated advanced HER2-positive gastric cancer
    Aylin Pamuk
    Fabian Kütting
    Hakan Alakus
    Christiane Bruns
    Der Onkologe, 2021, 27 (1): : 74 - 76
  • [8] Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer
    Modi, Shanu
    Saura, Cristina
    Yamashita, Toshinari
    Park, Yeon Hee
    Kim, Sung-Bae
    Tamura, Kenji
    Andre, Fabrice
    Iwata, Hiroji
    Ito, Yoshinori
    Tsurutani, Junji
    Sohn, Joohyuk
    Denduluri, Neelima
    Perrin, Christophe
    Aogi, Kenjiro
    Tokunaga, Eriko
    Im, Seock-Ah
    Lee, Keun Seok
    Hurvitz, Sara A.
    Cortes, Javier
    Lee, Caleb
    Chen, Shuquan
    Zhang, Lin
    Shahidi, Javad
    Yver, Antoine
    Krop, Ian
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (07): : 610 - 621
  • [9] Discovery and development of trastuzumab deruxtecan and safety management for patients with HER2-positive gastric cancer
    Kohei Shitara
    Eishi Baba
    Kazumasa Fujitani
    Eiji Oki
    Satoshi Fujii
    Kensei Yamaguchi
    Gastric Cancer, 2021, 24 : 780 - 789
  • [10] Discovery and development of trastuzumab deruxtecan and safety management for patients with HER2-positive gastric cancer
    Shitara, Kohei
    Baba, Eishi
    Fujitani, Kazumasa
    Oki, Eiji
    Fujii, Satoshi
    Yamaguchi, Kensei
    GASTRIC CANCER, 2021, 24 (04) : 780 - 789
12345